Adagene (ADAG)
(Delayed Data from NSDQ)
$2.37 USD
+0.47 (24.79%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.43 +0.06 (2.53%) 4:42 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADAG 2.37 +0.47(24.79%)
Will ADAG be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADAG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADAG
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
ADAG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Other News for ADAG
Adagene (ADAG) Coverage Initiated by Leerink Partners with $7 PT | ADAG Stock News
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Adagene (ADAG) Receives Outperform Rating from Leerink
Adagene initiated with bullish view at Leerink, here's why
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in ...